BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23053666)

  • 1. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.
    Lin X; Shang X; Manorek G; Howell SB
    PLoS One; 2013; 8(6):e67496. PubMed ID: 23805314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.
    Shang X; Lin X; Alvarez E; Manorek G; Howell SB
    Neoplasia; 2012 Oct; 14(10):974-85. PubMed ID: 23097631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Jaehde U
    J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
    Wang X; Jiang P; Wang P; Yang CS; Wang X; Feng Q
    PLoS One; 2015; 10(4):e0125402. PubMed ID: 25927922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer.
    Maeda T; Murata M; Chiba H; Takasawa A; Tanaka S; Kojima T; Masumori N; Tsukamoto T; Sawada N
    Prostate; 2012 Mar; 72(4):351-60. PubMed ID: 21656836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cisplatin induces drug resistance in human esophageal squamous carcinoma cell line EC109 by decreasing CTR1 protein expression].
    Yu L; Chen MH; Gu CP; Li YL; Wen J; Fu JH; Cho CH; Liu SW
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):801-4. PubMed ID: 21602128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
    Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
    Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
    Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
    Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential roles of claudin-3 and claudin-4 in ovarian cancer management.
    Uthayanan L; El-Bahrawy M
    J Egypt Natl Canc Inst; 2022 Jun; 34(1):24. PubMed ID: 35665865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.
    Rangel LB; Agarwal R; D'Souza T; Pizer ES; Alò PL; Lancaster WD; Gregoire L; Schwartz DR; Cho KR; Morin PJ
    Clin Cancer Res; 2003 Jul; 9(7):2567-75. PubMed ID: 12855632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
    Bompiani KM; Tsai CY; Achatz FP; Liebig JK; Howell SB
    Metallomics; 2016 Sep; 8(9):951-62. PubMed ID: 27157188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
    Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
    Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of Clostridium perfringens enterotoxin depends on the conditions of claudin-4 in ovarian carcinoma cells.
    Tanaka S; Aoyama T; Ogawa M; Takasawa A; Murata M; Osanai M; Saito T; Sawada N
    Exp Cell Res; 2018 Oct; 371(1):278-286. PubMed ID: 30142326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake.
    Lv X; Song J; Xue K; Li Z; Li M; Zahid D; Cao H; Wang L; Song W; Ma T; Gu J; Li W
    Mol Carcinog; 2019 May; 58(5):794-807. PubMed ID: 30614075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
    Blair BG; Larson CA; Safaei R; Howell SB
    Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.